<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01533155</url>
  </required_header>
  <id_info>
    <org_study_id>D3820C00011</org_study_id>
    <nct_id>NCT01533155</nct_id>
  </id_info>
  <brief_title>Study in Healthy Volunteers to Investigate the Effects of Quinidine on the Pharmacokinetics of NKTR-118</brief_title>
  <official_title>A Randomized, 2-Part, Crossover, Single Center Study to Evaluate Effect of Quinidine on the Pharmacokinetics of NKTR-118 and the Concomitant Effect of Quinidine and NKTR-118 on Morphine-induced Miosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      Study in healthy volunteers to investigate the effects of Quinidine on the Pharmacokinetics
      of NKTR-118
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, 2-Part, Crossover, Single Center Study to Evaluate Effect of Quinidine on the
      Pharmacokinetics of NKTR-118 and the Concomitant Effect of Quinidine and NKTR-118 on
      Morphine-induced Miosis
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Description of the pharmacokinetic (PK) profile for NKTR- 118 in terms of maximum observed plasma concentration (Cmax), time to Cmax (tmax), apparent terminal half-life (t1/2λz).</measure>
    <time_frame>At predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of the PK profile for NKTR- 118 in terms of apparent terminal rate constant (λz), area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC).</measure>
    <time_frame>At predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of the PK profile for NKTR 118 in terms of area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-t)].</measure>
    <time_frame>At predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of the PK profile for NKTR 118 in terms of area under the plasma concentration-time curve from time zero to 24 hours [AUC(0-24)].</measure>
    <time_frame>At predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours postdose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of the PK profile for NKTR 118 in terms of apparent oral clearance from plasma (CL/F), and apparent volume of distribution during the terminal phase (Vz/F).</measure>
    <time_frame>At predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours postdose.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of the safety profile in terms of adverse events, clinical laboratory assessments , vital signs (blood pressure and pulse rate), physical examinations, electrocardiograms and Columbia-Suicide Severity Rating Scale.</measure>
    <time_frame>From baseline up to 21 days.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of results from pupillary measurements in terms of size change from baseline on both eyes in mm. (Measurements in 4 different conditions: dark, 0.04 lux, 0.4 lux and 4 lux)</measure>
    <time_frame>Measurments from baseline day -1, and at 0.5, 1, 2, 3, 4, 6, and 24 hours post dose.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">214</enrollment>
  <condition>Drug Induced Constipation</condition>
  <arm_group>
    <arm_group_label>NKTR-118/ Quinidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One 25-mg NKTR-118 tablet will be administered once with 3 Quinidine 200mg tablets in the morning of period 1 or period 2 (part 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NKTR-118/ Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One 25-mg NKTR-118 tablet will be administered once with 3 Placebo tablets in the morning of period 1 or period 2 (part 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NKTR-118/ Quinidine/ Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One 25-mg NKTR-118 tablet will be administered with 3 Quinidine 200mg tablets with Morphine inj 5mg/70kg once in the morning on period 3 or period 4 (Part 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NKTR-118/ Placebo/ Morphine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One 25-mg NKTR-118 tablet will be administered with 3 placebo tables with Morphine inj 5mg/70kg once in the morning of period 3 or period 4 (part 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nektar 118</intervention_name>
    <description>Oral 25 mg tablet</description>
    <arm_group_label>NKTR-118/ Quinidine</arm_group_label>
    <arm_group_label>NKTR-118/ Placebo</arm_group_label>
    <arm_group_label>NKTR-118/ Quinidine/ Morphine</arm_group_label>
    <arm_group_label>NKTR-118/ Placebo/ Morphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quinidine</intervention_name>
    <description>Oral 200 mg tablet</description>
    <arm_group_label>NKTR-118/ Quinidine</arm_group_label>
    <arm_group_label>NKTR-118/ Quinidine/ Morphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quinidine placebo</intervention_name>
    <description>Oral Tablet</description>
    <arm_group_label>NKTR-118/ Placebo</arm_group_label>
    <arm_group_label>NKTR-118/ Quinidine/ Morphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>10 mg/ml, intravenously</description>
    <arm_group_label>NKTR-118/ Quinidine/ Morphine</arm_group_label>
    <arm_group_label>NKTR-118/ Placebo/ Morphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated, written informed consent prior to any study-specific
             procedures.

          -  Male and female (nonchildbearing potential, nonlactating) healthy volunteers aged 18
             to 55 years inclusive, with suitable veins for cannulation or repeated venipuncture.

          -  Female volunteers must be nonpregnant and nonlactating. Women of childbearing
             potential must have negative pregnancy test (screening and admission) and be using a
             highly-effective form of birth control for 3 months before enrollment.

          -  Male volunteers should be willing to use barrier contraception ie, condoms, from the
             first day of dosing until 3 months after dosing with the IP. The female partner should
             use contraception during this period.

          -  Volunteers must have a BMI between 18 and 30 kg/m2, inclusive, and weigh at least 50
             kg.

        Exclusion Criteria:

          -  Any clinically significant disease or disorder (eg, cardiovascular, pulmonary,
             gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine) which, may
             put the volunteer at risk of participation in the study, or influence of the ADME of
             drugs.

          -  Any clinically significant illness, medical/surgical procedure or trauma within 4
             weeks of the first administration of IP.

          -  Any clinically significant abnormalities in clinical chemistry, hematology, or
             urinalysis results as judged by the Investigator.

          -  History (personal or family) of torsades de pointes, any other polymorphic ventricular
             tachycardia, long QT syndrome, sudden death or Brugada syndrome, or personal history
             of sustained (greater than 30 s) monomorphic ventricular tachycardia.

          -  Abnormal vital signs, after 10 minutes supine rest as defined in protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phil Leese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Kansas United states</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Sostek, MD</last_name>
    <role>Study Director</role>
    <affiliation>Astrazeneca, Wilmington US</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bo Fransson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Astrazeneca, Sodertalje Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1393&amp;filename=Clinical_Study_Report_Synopsis_D3820C00011.pdf</url>
    <description>Clinical_Study_Report_Synopsis_D3820C00011</description>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2012</study_first_submitted>
  <study_first_submitted_qc>February 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2012</study_first_posted>
  <last_update_submitted>October 13, 2014</last_update_submitted>
  <last_update_submitted_qc>October 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Healthy male and female volunteers</keyword>
  <keyword>Drug-drug interaction</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>NKTR-118</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Naloxegol</mesh_term>
    <mesh_term>Quinidine</mesh_term>
    <mesh_term>Quinidine gluconate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

